Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
NCT03975387
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
106
Enrollment
INDUSTRY
Sponsor class
Stopped
Sponsor Decision
Conditions
Solid Tumor
Interventions
DRUG:
ASTX295
Sponsor
Taiho Oncology, Inc.